These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 16513409)

  • 1. High-mobility group box 1 (HMGB1) protein: friend and foe.
    Ulloa L; Messmer D
    Cytokine Growth Factor Rev; 2006 Jun; 17(3):189-201. PubMed ID: 16513409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-mobility group box-1 isoforms as potential therapeutic targets in sepsis.
    Parrish W; Ulloa L
    Methods Mol Biol; 2007; 361():145-62. PubMed ID: 17172710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cytokine activity of HMGB1.
    Yang H; Wang H; Czura CJ; Tracey KJ
    J Leukoc Biol; 2005 Jul; 78(1):1-8. PubMed ID: 15734795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMGB1, a potent proinflammatory cytokine in sepsis.
    Huang W; Tang Y; Li L
    Cytokine; 2010 Aug; 51(2):119-26. PubMed ID: 20347329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High mobility group box 1 protein as a late-acting mediator of acute lung inflammation.
    Lutz W; Stetkiewicz J
    Int J Occup Med Environ Health; 2004; 17(2):245-54. PubMed ID: 15387080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMGB1 as a DNA-binding cytokine.
    Andersson U; Erlandsson-Harris H; Yang H; Tracey KJ
    J Leukoc Biol; 2002 Dec; 72(6):1084-91. PubMed ID: 12488489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity.
    Bianchi ME; Manfredi AA
    Immunol Rev; 2007 Dec; 220():35-46. PubMed ID: 17979838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator.
    Erlandsson Harris H; Andersson U
    Eur J Immunol; 2004 Jun; 34(6):1503-12. PubMed ID: 15162419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cytokine activity of HMGB1--extracellular escape of the nuclear protein.
    Sun NK; Chao CC
    Chang Gung Med J; 2005 Oct; 28(10):673-82. PubMed ID: 16382751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High mobility group box 1 in the pathogenesis of inflammatory and autoimmune diseases.
    Voll RE; Urbonaviciute V; Herrmann M; Kalden JR
    Isr Med Assoc J; 2008 Jan; 10(1):26-8. PubMed ID: 18300566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-mobility group box-1 in ischemia-reperfusion injury of the heart.
    Andrassy M; Volz HC; Igwe JC; Funke B; Eichberger SN; Kaya Z; Buss S; Autschbach F; Pleger ST; Lukic IK; Bea F; Hardt SE; Humpert PM; Bianchi ME; Mairbäurl H; Nawroth PP; Remppis A; Katus HA; Bierhaus A
    Circulation; 2008 Jun; 117(25):3216-26. PubMed ID: 18574060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HMGB1: a two-headed signal regulating tumor progression and immunity.
    Campana L; Bosurgi L; Rovere-Querini P
    Curr Opin Immunol; 2008 Oct; 20(5):518-23. PubMed ID: 18599281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of high-mobility group box-1 in renal ischemia and reperfusion injury and the effect of ethyl pyruvate.
    Chung KY; Park JJ; Kim YS
    Transplant Proc; 2008 Sep; 40(7):2136-8. PubMed ID: 18790172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High mobility group box-1 as a therapeutic target downstream of tumor necrosis factor.
    Czura CJ; Yang H; Tracey KJ
    J Infect Dis; 2003 Jun; 187 Suppl 2():S391-6. PubMed ID: 12792856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of high mobility group box-1 protein in severe sepsis.
    Sunden-Cullberg J; Norrby-Teglund A; Treutiger CJ
    Curr Opin Infect Dis; 2006 Jun; 19(3):231-6. PubMed ID: 16645483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis.
    Andersson U; Tracey KJ
    Rheum Dis Clin North Am; 2004 Aug; 30(3):627-37, xi. PubMed ID: 15261345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dealing with death: HMGB1 as a novel target for cancer therapy.
    Lotze MT; DeMarco RA
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1405-9. PubMed ID: 14763124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
    Dong Xda E; Ito N; Lotze MT; Demarco RA; Popovic P; Shand SH; Watkins S; Winikoff S; Brown CK; Bartlett DL; Zeh HJ
    J Immunother; 2007 Sep; 30(6):596-606. PubMed ID: 17667523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Masquerader: high mobility group box-1 and cancer.
    Ellerman JE; Brown CK; de Vera M; Zeh HJ; Billiar T; Rubartelli A; Lotze MT
    Clin Cancer Res; 2007 May; 13(10):2836-48. PubMed ID: 17504981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1).
    van Beijnum JR; Buurman WA; Griffioen AW
    Angiogenesis; 2008; 11(1):91-9. PubMed ID: 18264787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.